Acrobiosystems Co.,Ltd. (301080.SZ) has been requested by the China Securities Regulatory Commission (CSRC) to provide supplementary information regarding the regulatory compliance of its overseas subsidiaries. The request pertains specifically to the fulfillment of procedures related to overseas investments and foreign exchange management.
According to a disclosure from Hong Kong Exchanges and Clearing Limited on January 26, Beijing Acrobiosystems Biotechnology Co., Ltd. has submitted an application for a main board listing in Hong Kong, with China Merchants Securities International acting as the sole sponsor.
The CSRC has asked Acrobiosystems to provide a detailed explanation of the specific implementation status of regulatory procedures involving overseas investments and foreign exchange management for its overseas subsidiaries. The company is required to engage legal counsel to verify this information and provide a clear legal opinion, including a conclusive statement on compliance.
The company's prospectus indicates that Acrobiosystems is a global provider of life science tools and technical services, dedicated to empowering biopharmaceutical companies across the entire value chain from R&D and production to clinical application. It offers a comprehensive product portfolio integrating high-quality biological reagents—including recombinant proteins, antibodies, assay kits, and other products—along with multiple technical services. The synergistic effects of its products enable the company to provide one-stop solutions addressing critical needs in biopharmaceutical R&D, from early-stage target discovery to clinical trials.
As of the latest practicable date, the company provides over 5,000 product SKUs and a diversified portfolio of technical services. All manufacturing and execution are conducted under stringent international quality standards, including ISO9001:2015, ISO13485:2016, cGMP, MDSAP, CNAS, and Rx360.
Comments